Caraco has addressed US 'Form 483' quality concerns, Sun confirms
This article was originally published in Scrip
Executive Summary
Sun Pharmaceutical Industries has said that its US arm, Caraco, has no pending unaddressed Form 483s, which pertain to the US FDA's observations on deficiencies in quality control systems, at its manufacturing sites, bringing relief to investors jittery over a spate of recent regulatory actions against a clutch of Indian firms.